Henry Schein, Inc.
HealthcareNASDAQ:HSIC · NASDAQ Global Select
+$1.03 today
Vol 1.08M · Avg 1.38M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.3%
avg 15.0%
ROIC
6.6%
avg 9.2%
ROA
3.5%
avg 5.8%
Analysis
ROE is currently the strongest return metric at 12.3% versus its period average of 15.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Andrea Albertini | Chief Executive Officer of Global Distribution & Technology | $1.77M | — | 56 | $120,691.00 | 0.11% |
Mark E. Mlotek | Executive Vice President & Chief Strategic Officer | $1.69M | — | 70 | $98,372.00 | 0.09% |
Michael Saul Ettinger | Executive Vice President & Chief Operating Officer | $1.43M | — | 65 | $112,208.00 | 0.10% |
Ronald N. South | Senior Vice President & Chief Financial Officer | $1.18M | — | 64 | $88,930.00 | 0.08% |
Michael Amodio | VP & Treasurer | — | — | — | $112,208.00 | 0.10% |
Christopher Pendergast | Senior Vice President & Chief Technology Officer | — | — | 63 | — | — |
Graham Stanley | Vice President of Investor Relations & Strategic Finance Project Officer | — | — | — | $253,279.00 | 0.22% |
Mark Hillebrandt | Vice President & Chief Data Revenue Officer | — | — | — | $98,372.00 | 0.09% |
R. Steven Boggan | Chief Executive Officer of Global Oral Reconstruction Group, Americas | — | — | 61 | $138,272.00 | 0.12% |
Ted Devries | CEO & President of The Exan Group | — | — | — | — | — |
Tom Popeck | Chief Executive Officer of Henry Schein Products Group | — | — | 56 | $86,182.00 | 0.08% |
Christine Sheehy | Senior Vice President & Chief Human Resources Officer | — | — | 58 | $18,454.00 | 0.02% |
Jennifer Ferrero | VP, Senior Counsel & Corporate Secretary | — | — | — | — | — |
Kelly Murphy | Senior Vice President & General Counsel | — | — | 45 | $34,812.00 | 0.03% |
Olga Timoshkina | VP of Corporate Finance & Chief Accounting Officer | — | — | — | — | — |
Frederick Lowery | CEO & Director | — | — | 55 | $177,116.00 | 0.16% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$1.36M
Sells
10
$8.58M
Net Sentiment
$7.21M
Net selling
Most Active
BERGMAN STANLEY M
5 transactions
1–10 of 12
Analysis
Insiders reported 2 buys worth $1.36M and 10 sells worth $8.58M over the last 12 months. That adds up to net selling of $7.21M. BERGMAN STANLEY M was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +9.7% | +6.3% (14yr)2 analysts |
| Revenue | N/A | N/A | +5.9% | +2.7% (14yr)5 analysts |
| Net Income | N/A | N/A | +7.3% | +3.9% (14yr)5 analysts |
| EBIT | N/A | N/A | +6.6% | +0.9% (14yr)5 analysts |
Analysis
Recent growth has been strongest in EPS at +9.7% over three years. Forward estimates point to EPS at +6.3% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
Globus Medical, Inc.
NYSE:GMED
$10.84B
Molina Healthcare, Inc.
NYSE:MOH
$10.43B
Masimo Corporation
NASDAQ:MASI
$9.42B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.24B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Grifols, S.A.
NASDAQ:GRFS
$6.46B
Avantor, Inc.
NYSE:AVTR
$6.41B
Who manages HSIC?
Henry Schein, Inc. (HSIC) lists 16 active executives. The top listed executive is Mark E. Mlotek, Executive Vice President & Chief Strategic Officer.
Are HSIC insiders buying or selling?
Recent insider activity shows net selling of $5.50M.
Explore More
Continue the stock analysis
Jump to another research area for this company.